This dose-response trend in Aβ plaque reduction in both size and putatively overall plaque counts following therapeutic dosing with VEN-02XX, further supports a putative role for NLRP3 in driving the Aβ plaque burden in AD. Here, NLRP3 is linked to Alzheimer disease.